Skip to main content

CORRECTION article

Front. Oncol., 07 March 2022
Sec. Pharmacology of Anti-Cancer Drugs

Corrigendum: Combined Scutellarin and C18H17NO6 Imperils the Survival of Glioma: Partly Associated With the Repression of PSEN1/PI3K-AKT Signaling Axis

Xiu-Ying He&#x;Xiu-Ying He1†Yang Xu&#x;Yang Xu1†Qing-Jie XiaQing-Jie Xia1Xiao-Ming ZhaoXiao-Ming Zhao1Shan LiShan Li2Xiao-Qiong He*Xiao-Qiong He3*Ru-Rong Wang*Ru-Rong Wang1*Ting-Hua Wang,*Ting-Hua Wang1,2*
  • 1Institute of Neurological Disease, Department of Anesthesiology, Translational Neuroscience Center, West China Hospital, Sichuan University, Chengdu, China
  • 2Institute of Neuroscience, Laboratory Zoology Department, Kunming Medical University, Kunming, China
  • 3School of Public Health, Kunming Medical University, Kunming, China

Corrigendum on:
Combined Scutellarin and C18H17NO6 Imperils the Survival of Glioma: Partly Associated With the Repression of PSEN1/PI3K-AKT Signaling Axis

by He X-Y, Xu Y, Xia Q-J, Zhao X-M, Li S, He X-Q, Wang R-R, and Wang T-H (2021) Front. Oncol. 11:663262. doi: 10.3389/fonc.2021.663262

The shared equal contribution made by authors Xiu-Ying He, and Yang Xu was not depicted in the article. These authors have contributed equally to this work.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: C18H17NO6, PSEN1, glioma, PI3K-Akt signaling, scutellarin

Citation: He X-Y, Xu Y, Xia Q-J, Zhao X-M, Li S, He X-Q, Wang R-R and Wang T-H (2022) Corrigendum: Combined Scutellarin and C18H17NO6 Imperils the Survival of Glioma: Partly Associated With the Repression of PSEN1/PI3K-AKT Signaling Axis. Front. Oncol. 12:872110. doi: 10.3389/fonc.2022.872110

Received: 09 February 2022; Accepted: 10 February 2022;
Published: 07 March 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 He, Xu, Xia, Zhao, Li, He, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ting-Hua Wang, tinghua_neuron@263.net; Ru-Rong Wang, wangrurong@scu.edu.cn; Xiao-Qiong He, hexqcn@aliyun.com

These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.